Xuanzhu Biopharm set for spin-off in Hong Kong IPO
The cash-strapped company has launched a drug to treat duodenal ulcers and is seeking approval for other products, but is up against a host of competing medicines Key Takeaways: Xuanzhu…
0460.HK
Recent Articles
Discover hidden China stock gems in our weekly newsletter